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ABSTRACT
Clinical rationale for study. The sudden onset of autoimmune neurological diseases often threatens life. In such clinical 
situations, fast, effective and safe treatment is needed. Therapeutic plasma exchange (TPE) is an option in the treatment 
of autoimmune disorders. 
Aim of study. The aim was to assess the tolerability and safety of membrane-based therapeutic plasma exchange (mTPE) 
in patients with autoimmune neurological diseases.
Materials and methods. A total of 410 TPE treatments were performed in 91 adult patients. The main reasons for 
performing TPE were: Guillain-Barre syndrome (39.56%), chronic inflammatory demyelinating polyradiculoneuropathy 
(20.88%), and myasthenia gravis (17.58%). 
Results.  A total of 183 (44.6%) mTPE treatments were performed without complications. In 18 (19.8%) pa-
tients, there were no complications observed in any of the mTPE procedures (a total of 83 procedures). Se-
rious and life-threatening complications occurred during four (0.97%) mTPEs. The most common abnor-
mality in laboratory tests was hypocalcaemia. In patients with a fibrinogen concentration ≥ 2.63 g/L, me-
asured before the second plasmapheresis, coagulation in the TPE filter was more frequently observed (p = 0.04). 
Conclusions and clinical implications. Our study proves that the use of plasmapheresis conducted by filtration in the 
treatment of autoimmune neurological diseases is safe and well tolerated. 
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Introduction
Therapeutic plasma exchange (TPE) is a clinical proce-
dure for the replace of plasma, which aims to remove the 
immune system’s extracellular components and the pro-
inflammatory agents from the blood. These factors are of key 
importance in the pathogenesis of many diseases, including 
those affecting the nervous system. During TPE, the patient’s 
plasma is separated and removed. Along with the patient’s 
plasma, we remove specific, potentially pathogenic factors 
such as: antibodies (Ag) including alloantibodies, monoc-
lonal protein, circulating immune complexes, complement 
activation products, cytokines, atherogenic substances, and 
toxic compounds. TPE is thought to affect the immune sy-
stem by: improving the function of the reticuloendothelial 
system; removing inflammatory mediators; changing antigen 
proportions and antibodies leading to the formation of better 
soluble immune complexes; and stimulating a lymphocyte 
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population sensitised to cytotoxic treatment with which the 
plasma exchange is often associated. TPE also allows for 
supplementing the deficiencies of specific plasma factors 
[1–2]. In the current American Society for Apheresis (ASFA) 
guidelines, therapeutic plasma exchange is recommended for 
the treatment of 157 conditions. Disorders of the nervous 
system include 25 disease entities. TPE is most commonly 
used in Guillain-Barre syndrome (GBS), neuromyelitis 
optica spectrum disorders (NMOSD), myasthenia gravis 
(MG), Multiple Sclerosis (MS), and chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) [2]. Also, in 
the latest update to the guidelines, two out of six new dise-
ases listed are neurological or possibly involve the nervous 
system: amyotrophic lateral sclerosis, and POEMS syndrome 
(POEMS = polyneuropathy, organomegaly, endocrinopathy, 
monoclonal protein, skin changes) [2]. In the ASFA re-
commendations, indications for TPE are divided into four 
therapeutic categories, the first being where TPE treatment 
is the basic and preferred method of therapy, and the fourth 
category being where the use of TPE is ineffective and may 
even be harmful. In our dialysis centre, therapeutic plasma 
exchange is mainly performed in patients with autoimmune 
neurological diseases. 
Clinical rationale for the study
The aim of this study was to assess the tolerability and 
safety of membrane-based therapeutic plasma exchange 
(mTPE) in patients with autoimmune neurological diseases.
Materials and methods
Our study involved patients treated with therapeutic 
plasma exchange for neurological indications between March 
2013 and October 2017. In most of the disease entities, the 
TPE treatment was combined with pharmacotherapy in accor-
dance with current recommendations. The data was assessed 
retrospectively based on the patients’ medical records. The 
number and percentage of patients treated with TPE classified 
by category and the ASFA TPE grading recommendations are 
presented in Table 1 [2]. 
TPE was performed by filtration (mTPE) using the Gambro 
Prismaflex apparatus. Vascular access was obtained by intro-
ducing a two-lumen vascular catheter into the internal jugular, 
subclavian or femoral veins using the Seldinger technique. 
In all cases, cannulas sized 13.5 Fr/15 cm or 13.5 Fr/20 cm 
were inserted. For the TPE treatments, ready-made sets of 
capillary tubing and plasma filters from Gambro Prismaflex 
TPE 2000 were used, and prior to the procedure these were 
filled with saline and vented. Therapeutic plasma exchange was 
usually performed every two days. The duration of any single 
treatment did not exceed four hours. The number and mode 
of treatments depended on the clinical status of the patient 
and their underlying condition. On average, patients received 
both 1,000–1,500 mL of crystalloids (multi-electrolyte fluid, 
0.9% NaCl solution) and 1,000–1,500 mL of colloids. The total 
volume of plasma to be exchanged (EPV) was calculated based 
on the patient’s haematocrit (Hct) level and body weight using 
the Kaplan formula: 
EPV = [0.065 × body weight (kg)] × [1-Hct].
Where anticoagulation was required, unfractionated he-
parin was used, with an initial dose of 50 IU/kg body weight 
(2,000–3,000 IU on average) followed by a continuous intrave-
nous infusion of unfractionated heparin at a dose of 1,000 IU/ 
/hour. In patients showing a severe clinical condition, with an 
increased risk of bleeding complications, or in the case of repe-
ated problems with plating of the plasma filter, 2–3 activated-
-clotting time (ACT) measurements were taken at the bedside. 
ACT values were kept between 90–130 s. The blood flow rate 
was kept at 100-110 ml/min, and transmembrane pressure 
(TMP) was within 20–60 mmHg. During mTPE, the patient’s 
vital signs (blood pressure, heart rate using continuous ECG 
recording, oxygen saturation, frequency and character of 
breathing, body temperature, state of consciousness) and any 
possible side effects were closely monitored. In addition, the 
patient’s skin layers were observed for the presence of urticaria 
or erythema. The technical parameters of the procedure were 
regularly monitored: TMP, arterial pressure, venous pressure, 
Table 1. Indications for PTE in our study, and category and grade recommendations for TPE according to the ASFA [2]
Neurological disorders Indication Category Grade Number/percentage 
of treated patients
Acute disseminated encephalomyelitis Steroid refractory II 2C 7/7.69
Acute inflammatory demyelinating 
polyradiculoneuropathy(Guillain-Barre syndrome)
Primary treatment I 1A 36/39.57
Chronic inflammatory demyelinating polyradiculoneuro-
pathy
 Severe relapse or steroid 
refractory 
I 1B 19/20.89
Multiple Sclerosis Rapidly evolving MS III 2B 10/10.99
Myasthenia gravis Moderate-to-severe 
symptoms
I 1B 16/17.58
Neuromyelitis optica spectrum disorders Severe relapse or steroid 
refractory
II 1B 3/3.3
ASFA — American Society for Apheresis
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ultrafiltration, blood flow, and flow and temperature of sub-
stitution fluids. 
In accordance with the protocols adopted by our dialy-
sis centre, before the second mTPE, patients’ blood counts, 
prothrombin time expressed as the international normalised 
ratio (INR), activated partial thromboplastin time (APTT), 
fibrinogen concentrations, potassium, magnesium, total pro-
tein, and serum albumin were each recorded and evaluated.
Complications observed during mTPE were divided using 
the World Apheresis Association (WAA) categories into 
mild (self-limiting without treatment), medium (requiring 
additional drugs during TPE), severe (being the reason for 
discontinuing the TPE treatment), and death [3]. 
Statistical analysis
Data was presented as the number of patients (the percenta-
ge of the group) for nominal variables, and as a median (lower-
-upper quartile). Distribution normality was assessed using the 
Shapiro-Wilk test. Where normality assumptions were not met, 
the differences between the two groups were tested using the 
Mann-Whitney U test. The Wilcoxon pairs order test was used 
to show the effect of the procedure on the patients’ conditions. 
The dependence between the type of substitution fluid and the 
appearance of a clot in the dialysis set was demonstrated using 
the Chi-square independence test with the Yetsa correction. For 
the ROC curve analysis, cut-off values optimizing the Youden 
index were calculated. The predictability of clotting in the 
therapeutic plasma exchange kit was determined by the fibri-
nogen level. Results were statistically significant at p < 0.05. The 
Statistica 13.1 package (StatSoft) was used in the calculations.
Results
Over the course of 56 months, 410 mTPEs were performed 
in 91 patients aged between 18 and 88 years (mean 53.9). Men 
comprised 58 of the patients, women 33. 
In the group of patients who qualified for mTPE, the fol-
lowing comorbidities were most often observed: hypertension 
(n = 43; 47.25%), osteoarthritis (n = 17; 18.68%), diabetes or 
impaired glucose tolerance (n = 12; 13.19%), current or history 
of cancer (n = 11; 12.1%), hypothyroidism (n = 11; 12.1%), 
history of Lyme disease (n = 10; 10.9%), and infections of the 
urinary or respiratory systems (n = 9; 9.89%). Other diseases, 
such as hypercholesterolemia, chronic kidney disease, periphe-
ral osteoarthritis, vascular damage to the central nervous sy-
stem, liver damage, obesity, epilepsy, chronic pancreatitis, and 
atrial fibrillation were observed in less than 10% of patients.
The number of procedures performed in one patient 
ranged from 1–7 (average 4.5). The patient who underwent 
one mTPE developed massive allergic symptoms after the al-
bumin solution was transfused. The largest group, consisting 
of almost 1/3 of the patients treated with mTPE, were those 
with Guillain-Barre syndrome. Table 1 shows the number 
and percentage of patients treated for neurological disorders. 
A total of 183 (44.6%) mTPE treatments were performed 
without complications. In 18 (19.8%) patients there were no 
complications observed in any of the mTPE procedures (a total 
of 83 procedures). In the remaining patients, at least one mTPE 
procedure resulted in one or more complications. 
We observed mild complications in 44 (48.3%) patients 
during 80 (19.5%) mTPE procedures, and moderate com-
plications, requiring the administration of additional drugs, 
in 76 (83.5%) patients during 119 (29%) procedures. Table 
2 presents the type, number and percentage of complications 
during TPE, with their severity measured according to WAA 
[3]. Of the 96 patients undergoing TPE, three (3.2%) died. 
Deaths were a consequence of a severe course of the underlying 
disease (diffuse inflammation of the brain and spinal cord in 
two patients) or complications of the underlying disease (in 
one patient a myasthenic crisis with sepsis resulting from 
massive pneumonia). All deaths occurred long after the end 
of mTPE treatments, and were not related to the therapeutic 
plasma exchange.
After analysing the results of tests taken before the second 
TPE, we prepared Table 3, in which we identified the irreg-
ularities found in the test results along with the frequency 
of their occurrence in the studied population. In addition, it 
was observed that in patients with fibrinogen concentration 
≥ 2.63 g/L, measured before the second plasmapheresis, 
coagulation in the TPE filter was more frequently observed 
(p = 0.04). The observed regularity is shown in Figure 1. Chan-
ges in other blood parameters did not significantly affect the 
complications associated with the TPE technique.
There was no correlation between age and complications 
related to mTPE in the study group (p < 0.05). No correlation 
was observed between the conditions that are an indication for 
TPE and the complications observed during mTPE. 
Technical problems with the catheter were observed sig-
nificantly more frequently in patients with concomitant Lyme 
disease (p = 0.005), and paresthesia during mTPE was more 
common in patients with vascular CNS damage (p = 0.05).
Discussion
Our work is one of few original papers to have summarised 
the use of therapeutic plasma exchange in neurological disor-
ders [4–6]. The work presented here is the result of a five-year 
period of conducting therapeutic plasma exchange by the 
filtration method in our dialysis centre. In our study, most of 
the indications for TPE were in the first and second categories 
according to the ASFA recommendations [2].
TPE is an invasive method of treatment and carries a risk 
of complications, but in most cases these are mild; in our 
study, their frequency was estimated at 18.6%. This percentage 
is much higher than in WAA data, in which mild complica-
tions occurred in 2.8% of TPE treatments from all indications; 
although in the WAA report only 17% of patients had neuro-
logical disorders [3]. In addition, some of the complications 
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Table 2. Type, number and percentage of complications with severity according to WAA grading scale in course of TPE treatment
Grading of adverse 
event
Symptoms/findings Patients with  
complications (n/%)
TPE with  
complications (n/%)
Mild Hypotension not requiring replacement of pressure amines





Moderate TMP increase or coagulation in the filter



























































Death – 0  0
HIT II — heparin-induced thrombocytopenia type II; TMP — transmembrane pressure; TRALI — transfusion-related acute lung injury; WAA — World Apheresis Association
Table 3. Irregularities in laboratory tests taken before second TPE
Type of irregularity Number and percentage of patients (n/%) with  
laboratory irregularities (n = 78)
Anaemia (Hgb † < 12 g/dL for women and < 13.0 g/dL for men) 28/29.17
Leukopenia (leucocytes < 4,000/μ) 1/1.04
Elevated leucocytosis (leukocyte count > 11,000/μ) 41/42.7
Thrombocytopenia (platelet count < 100,000/μ) 14/14.58
Hypokalaemia (serum potassium < 3.5 mml/L) 6/6.25
Hyponatraemia (serum sodium < 135 mmol/L) 21/21.87
Hypocalcaemia (decrease in total serum calcium < 2.25 mmol/L) 49/51.04
Hypomagnesaemia (magnesium concentration < 0.65 mmol/L) 21/21.87
Lowered fibrinogen concentration (< 1.8 g/L) 16/16.66
eGFR ‡ < 60 mL/min/1.73m2 5/5.2
Reduced total protein levels < 66 g/L 75/96.15
Decreased albumin level < 35 g/L 12/12.5
INR§ < 0.8 or > 1.2 2/2.08
APTT ¶ < 24 s or > 36 s 10/10.42
†Haemoglobin; ‡estimated Glomerular Filtration Rate; §International Normalised Ratio; ¶Activated Partial Thromboplastin Time 
348
Neurologia i Neurochirurgia Polska 2020, vol. 54, no. 4
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
the lack of this, we did not find any increased symptoms that 
may be related to hypocalcaemia.
In our study, the next most frequently observed abnor-
mality in the laboratory tests, observed in just over 40% of 
patients, was increased leucocytosis, which is probably related 
to the higher incidence of infection in this group of patients 
who were burdened with immune disorders resulting from the 
primary disease process and numerous co-morbidities. The 
immunosuppressive treatment used in some patients undergo-
ing TPE treatment, including systemic glucocorticoids, is also 
important. An important role in the decline in immunity in 
patients treated with therapeutic plasma exchange is played 
by the depletion of immunoglobulins and the complement 
component C3-C4 [3, 7]. 
All the factors described above help explain the relatively 
higher frequency of septic complications occurring in this 
group of patients. We suggest that both laboratory tests and 
increased and reliable observations of the patient are required 
to look for signs of infection. 
In our study, we observed that if the patient started 
a second mTPE with a fibrinogen concentration equal to or 
higher than 2.63 g/L, then he or she was more likely to clot 
in the filter during mTPE. In addition, it is important that 
the removal of a significant amount of antithrombin and 
other anticoagulants from the body can result in venous 
thromboembolism including pulmonary embolism [2]. Our 
work is probably the first to draw attention to the value of 
fibrinogen on the course of the mTPE procedure. In our work, 
unfractionated heparin was used as an anticoagulant during 
TPE treatment. However, we are aware of reports in which the 
authors describe the possibility of using TPE with filtration 
without using an anticoagulant [7–9]. For instance, Gashti et 
al. reported a 7.7% incidence of clotting of the filter requiring 
cartridge/filter replacement, and they suggested that TMP 
should be closely monitored [8]. 
The pathogenesis of adverse reactions during TPE should 
consider the lower efficacy of pharmacotherapy in patients 
treated with therapeutic plasma exchange. Drugs that are 
extensively removed during therapeutic plasma exchange 
include those characterised by low distribution volume and 
strong protein binding such as: acetylsalicylic acid, cefazolin, 
ceftriaxone, chlorpropamide, diclofenac, heparin, ibuprofen, 
valproic acid, warfarin, and thyroxine [10]. Considering 
the above observations, it is usually recommended that all 
scheduled drugs should be administered immediately after 
the therapeutic plasma exchange procedure [11].
Clinical implications
TPE conducted by filtration is relatively safe in the treat-
ment of neurological disorders, and the benefits of its use in 
autoimmune disease outweigh the risk of complications. Fibri-
nogen concentration ≥ 2.63 g/L, measured before the second 
TPE, significantly predisposes to the appearance of clotting 
Mann-Whitney 






















Figure 1. The effect of blood fibrinogen on the presence of clots 
in a TPE kit
that occur can be included in patients’ subjective feelings, 
such as: pain in various places, paresthesia, or pruritus, and 
these may actually result from the course of the underlying 
disease and thus affect the higher rate of TPE complications 
that we observed.
Our study confirmed the findings of earlier reports that 
patients who undergo albumin replacement therapy are more 
likely to have pressure drops during TPE than those in whom 
FFP was used in the substitution [3]. In our patients, severe 
life-threatening complications accompanied only four treat-
ments (0.97%). In the WAA report, severe complications after 
apheresis occurred in less than 1% of cases, which confirms 
that it is a safe method [3]. The most common abnormalities 
in laboratory tests were hypocalcaemia caused, inter alia, by 
the binding of calcium ions by citrate, which is a component 
of fresh frozen transfusion plasma, or the removal of calcium 
from the vascular bed as a consequence of the plasma ex-
changing with liquids that either do not contain, or have a low 
concentration of, calcium ions. Hypocalcaemia lowers the cell 
excitability threshold and may be responsible for several tetany 
and paraesthesia symptoms. During mTPE conducted in our 
centre, symptoms that may be a consequence of hypocalcae-
mia were usually slightly intensified, but they could cause 
the patient discomfort or anxiety. Due to reports of frequent 
complications in the routine use of calcium carbonate in the 
prophylaxis of hypocalcaemia accompanying mTPE [3], in 
2016 our centre ceased routine calcium substitution. Despite 
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in the TPE kit. Complications observed during TPE may be 
related to concomitant diseases that are not indications for TPE.
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